Literature DB >> 26467453

Prognosis of Ulcerative Colitis-Associated Colorectal Carcinoma Compared to Sporadic Colorectal Carcinoma: A Matched Pair Analysis.

Christine Leowardi1, Marie-Luise Schneider2, Ulf Hinz2, Jonathan M Harnoss2, Ignazio Tarantino2, Felix Lasitschka3, Alexis Ulrich2, Markus W Büchler2, Martina Kadmon2.   

Abstract

BACKGROUND: Ulcerative colitis (UC) patients have an increased risk of developing colorectal carcinoma (CRC). In contrast to clinical and pathogenetic differences, little is known about how prognosis compares between these patients and those with sporadic CRC. The aim of this study was to compare their characteristics and prognosis and identify independent risk factors for patients with UC-associated CRC.
METHODS: A total of 126 patients who underwent surgery in our department (1984-2010) for UC-associated (n = 63) or sporadic (n = 63) CRC were included in this analysis. Patients were matched according to sex, tumor location, and disease stage. Clinical parameters and overall, recurrence-free, and disease-specific survival were compared. In subgroup analyses, clinical parameters of UC patients were correlated with survival.
RESULTS: Median follow-up was 129 months in the UC group and 99 months in the sporadic CRC group. UC patients were significantly younger and had more multifocal, high-grade, and mucinous carcinomas. Five-year overall survival rate for UC-associated and sporadic CRC was similar (65.7 vs. 63.2%, p = 0.98). Recurrence-free survival for International Union Against Cancer (UICC) stage II disease was superior in the sporadic CRC group (p = 0.039). In a subgroup analysis of UC patients, a shorter duration of UC (p = 0.045) and male sex (p = 0.005) were associated with a worse prognosis.
CONCLUSIONS: Despite multiple clinical and histopathologic differences between UC-associated and sporadic CRC patients, overall survival and disease-specific survival are similar. In a subgroup analysis of UC patients with CRC, female sex was associated with a significantly better prognosis. This finding implies that estrogens may play a protective role in UC-associated CRC carcinogenesis.

Entities:  

Mesh:

Year:  2015        PMID: 26467453     DOI: 10.1245/s10434-015-4915-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.

Authors:  Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke
Journal:  Int J Colorectal Dis       Date:  2017-01-11       Impact factor: 2.571

2.  Long-Term Outcomes After Colorectal Surgery in Patients with Ulcerative Colitis-Associated Colorectal Cancer Versus Sporadic Colorectal Cancer.

Authors:  Viviane A Lin; Robin Lohse; Michael T Madsen; Tina Fransgaard; Feza H Remzi; Ismail Gögenur
Journal:  Ann Surg Oncol       Date:  2021-09-05       Impact factor: 5.344

3.  Cancer stem cell markers CD44v9+/CD133- are associated with low apoptosis in both sporadic and ulcerative colitis-associated colorectal cancers.

Authors:  Eriko Nakagomi; Tetuo Mikami; Kimihiko Funahashi; Shinichi Okazumi; Kazutoshi Shibuya; Nobuyuki Hiruta; Yoshinori Igarashi
Journal:  Histol Histopathol       Date:  2022-02-28       Impact factor: 2.130

4.  Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Authors:  Rona Yaeger; Manish A Shah; Vincent A Miller; Judith R Kelsen; Kai Wang; Zachary J Heins; Jeffrey S Ross; Yuting He; Eric Sanford; Rhonda K Yantiss; Sohail Balasubramanian; Philip J Stephens; Nikolaus Schultz; Moshe Oren; Laura Tang; David Kelsen
Journal:  Gastroenterology       Date:  2016-04-08       Impact factor: 22.682

5.  MiR-205 and MiR-373 Are Associated with Aggressive Human Mucinous Colorectal Cancer.

Authors:  Annette Eyking; Henning Reis; Magdalena Frank; Guido Gerken; Kurt W Schmid; Elke Cario
Journal:  PLoS One       Date:  2016-06-06       Impact factor: 3.240

Review 6.  p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer.

Authors:  Kazuhiro Kobayashi; Hiroyuki Tomita; Masahito Shimizu; Takuji Tanaka; Natsuko Suzui; Tatsuhiko Miyazaki; Akira Hara
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

Review 7.  KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.

Authors:  Lijun Du; John J Kim; Jinhua Shen; Binrui Chen; Ning Dai
Journal:  Oncotarget       Date:  2017-03-28

8.  Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis.

Authors:  Yoon Dae Han; Mahdi Hussain Al Bandar; Audrius Dulskas; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  BMC Surg       Date:  2017-03-21       Impact factor: 2.102

Review 9.  Immunological Mechanisms in Inflammation-Associated Colon Carcinogenesis.

Authors:  Takehiro Hirano; Daisuke Hirayama; Kohei Wagatsuma; Tsukasa Yamakawa; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

10.  Colorectal cancer in Crohn's colitis is associated with advanced tumor invasion and a poorer survival compared with ulcerative colitis: a retrospective dual-center study.

Authors:  Leonie E Vetter; Susanne Merkel; Alan Bénard; Christian Krautz; Maximilian Brunner; Anke Mittelstädt; Nicolas Schlegel; Armin Wiegering; Christoph-Thomas Germer; Klaus Weber; Robert Grützmann; Georg F Weber
Journal:  Int J Colorectal Dis       Date:  2020-09-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.